Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: DiaGenic Names de Potocki as CEO

Premium

DiaGenic has named Paul de Potocki as president and CEO, effective in September.

De Potocki will succeed Henrik Lund, who had been DiaGenic's interim CEO since April. He most recently served as CEO of Aerocrine. He has also served as senior vice president of commercial and strategic development at Biovitrium; and executive vice president of strategic marketing at Fresenius Kabi.

Oslo-based DiaGenic has developed technology to identify gene expression signatures in peripheral blood and the company is focused on developing biomarkers in the field of Alzheimer’s and Parkinson’s diseases. DiaGenic’s Alzheimer’s disease development program includes the CE-marked diagnostic test ADtect for detection of mild to moderate Alzheimer’s disease, and MCItect, which is under development for identifying patients with very early stages of Alzheimer’s disease.

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.